CARA

Cara Therapeutics carries an Underweight rating with 2/5 conviction, reflecting a 27.4 composite that remains well below a constructive threshold. Regulatory is the strongest pillar at 49, supported by a 50 jurisdiction posture and an 80 enforcement subscore, partly offset by a 25 filing-cadence contribution. Market contributes 40 despite the absence of an available quote, limiting confirmation from institutional pricing feeds. Editorial contributes 30, with no newsroom or brief activity recorded in CIN newsroom coverage. Fundamentals contribute only 2, making operating performance the principal drag and reinforcing the stretched financial condition.

Licensed fundamentals data show revenue contracting 51.6% year over year, while gross margin stands near negative 410% and operating margin near negative 412%. Those readings indicate that the revenue base does not currently support the company’s cost structure. EBITDA is negative $55.6 million, against reported net income of zero, and the 6.85 cash-burn ratio supports only a 15 cash-runway subscore rather than a broader balance-sheet endorsement. Market capitalization is approximately $8.1 million, consistent with the zero mcap-tier subscore. Primary regulatory filings show no recorded event during either the trailing 90-day or 180-day windows, no enforcement hits, and no available latest-filing timestamp. That sparse cadence explains why the regulatory pillar, although strongest, remains below the jurisdiction and enforcement components that support it.

The clearest rerating catalyst sits within the regulatory pillar because it already provides the highest contribution to the composite. A substantive primary regulatory filing could lift the weak cadence component, create a measurable event record, and provide the market pillar with information capable of restoring price discovery. CIN newsroom coverage could then convert that development into editorial traction, but such follow-through remains secondary to the filing itself. Operating improvement would still require reversal of the revenue contraction and deeply negative margins, while the stretched financial condition keeps fundamental support minimal. The single most important signal to watch is the appearance of a substantive new primary regulatory filing.